|
1) Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6: 2969-72
|
|
|
|
2) Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci. 2006; 97: 1-7
|
|
|
|
|
3) Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004; 28: 977-87
|
|
|
|
|
|
4) Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53: 549-54
|
|
|
|
|
|
5) Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003; 163: 1255-60
|
|
|
|
|
|
6) Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425: 851-6
|
|
|
|
|
|
7) Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003; 425: 846-51
|
|
|
|
|
|
8) Prasad NB, Biankin AV, Fukushima N, et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005; 65: 1619-26
|
|
|
|
|
|
9) Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997; 57: 3126-30
|
|
|
|
|
|
10) Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 1998; 58: 4740-4
|
|
|
|
|
|
11) Furukawa T, Fujisaki R, Yoshida Y, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol. 2005; 18: 1034-42
|
|
|
|
|
|
12) Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366: 704-7
|
|
|
|
|
|
13) Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003; 17: 3112-26
|
|
|
|
|
|
14) Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004; 95: 7-11
|
|
|
|
|
|
15) Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119: 861-72
|
|
|
|
|
|
16) Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chro-mosome 18q21. 1. Science. 1996; 271: 350-3
|
|
|
|
|
|
17) Zhang Y, Feng X-H, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-b-induced transcription. Nature. 1998; 394: 909-13
|
|
|
|
|
|
18) Duda DG, Sunamura M, Lefter LP, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene. 2003; 22: 6857-64
|
|
|
|
|
|
19) Groom LA, Sneddon AA, Alessi DR, et al. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 1996; 15: 3621-32
|
|
|
|
|
|
20) Furukawa T, Sunamura M, Motoi F, et al. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol. 2003; 162: 1807-15
|
|
|
|
|
|
21) Xu S, Furukawa T, Kanai N, et al. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet. 2005; 50: 159-67
|
|
|
|
|
|
22) Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res. 2006; 66: 95-106
|
|
|
|
|
|
23) Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003; 4: 437-50
|
|
|
|
|
|
24) Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7: 469-83
|
|
|
|
|
|
25) Brune K, Abe T, Canto M, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006; 30: 1067-76
|
|
|
|
|
|
26) Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999; 154: 1835-40
|
|
|
|
|
|
27) Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006; 3: e516
|
|
|
|
|
|
28) Zogopoulous G, Rothenmund H, Eppel A, et al. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet. 2007; 121: 635-7
|
|
|
|
|
|
29) Slater E, Amrillaeva V, Fendrich V, et al. Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med. 2007; 4: e164
|
|
|
|
|